Evidence map›Paper›PMID 40422009›Full record

ArticleBiosensors2025

Activation and Expansion of Human T-Cells Using Microfluidic Devices.

Ana Belén Peñaherrera-Pazmiño, Gustavo Rosero, Dario Ruarte, Julia Pinter, Karla Vizuete, Maximiliano Perez, Marie Follo, Betiana Lerner, Roland Mertelsmann

Abstract read
In one paragraph

Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ana Belén Peñaherrera-PazmiñoCentro de Investigación Biomédica (CENBIO), Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito 170527, Ecuador.ORCID 0000-0002-3886-7297
Gustavo RoseroIngeniería de Recubrimientos Especiales y Nanoestructuras (IREN) Center, National Technological University, Buenos Aires 1706, Argentina.ORCID 0000-0002-1254-6719
Dario RuarteDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg im Breisgau, Germany.ORCID 0000-0002-8373-2084
Julia PinterDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg im Breisgau, Germany.ORCID 0009-0004-9019-6461
Karla VizueteCentro de Nanociencia y Nanotecnología, Universidad de las Fuerzas Armadas ESPE, Sangolqui 1711031, Ecuador.ORCID 0000-0002-8912-5402
Maximiliano PerezIngeniería de Recubrimientos Especiales y Nanoestructuras (IREN) Center, National Technological University, Buenos Aires 1706, Argentina.
Marie FolloDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg im Breisgau, Germany.ORCID 0000-0002-3090-7442
Betiana LernerIngeniería de Recubrimientos Especiales y Nanoestructuras (IREN) Center, National Technological University, Buenos Aires 1706, Argentina.ORCID 0000-0003-3341-5686
Roland MertelsmannDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79085 Freiburg im Breisgau, Germany.

Funding

Mertelsmann Foundation gGmbH Biothera FoundationNational Scientific and Technical Research Argentinian Council (CONICET) PICT 2021-00058, PICT 2021 GRF-00464, PICT 2021-00167, PICT 2020 SERIEA-01571, PICT STARTUP 2020-0017, PICT 2021-00124UTE University Internal budget
6 · The paper itself

Abstract

Treatment of cancer patients with autologous T-cells expressing a chimeric antigen receptor (CAR) is one of the most promising therapeutic modalities for hematological malignancy treatment. For this treatment, primary T-cell expansion is needed. Microfluidic technologies can be used to better understand T-cell activation and proliferation. Microfluidics have had a meaningful impact in the way experimental biology and biomedical research are approached in general. Furthermore, microfluidic technology allows the generation of large amounts of data and enables the use of image processing for analysis. However, one of the major technical hurdles involved in growing suspension cells under microfluidic conditions is their immobilization, to avoid washing them out of the microfluidic chip during medium renewal. In this work, we use a multilevel microfluidic chip to successfully capture and immobilize suspension cells. Jurkat cells and T-cells are isolated through traps to microscopically track their development and proliferation after activation over a period of 8 days. The T-cell area of four independent microchannels was compared and there is no statistically significant difference between them (ANOVA

Indexed as

Lab-On-A-Chip DevicesLymphocyte ActivationMicrofluidic Analytical TechniquesT-LymphocytesCell ProliferationHumansJurkat Cellshealthmicrofluidicssuspension cellsT-cell expansion

Identifiers

PMID40422009
PMCPMC12110087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.